Welcome to our dedicated page for Vor Biopharma news (Ticker: VOR), a resource for investors and traders seeking the latest updates and insights on Vor Biopharma stock.
Vor Biopharma Inc. develops telitacicept for autoimmune diseases, with company updates centered on clinical development, financing, governance and employee equity compensation. Telitacicept is described by the company as a dual BAFF/APRIL inhibitor and novel dual-target fusion protein for autoantibody-driven conditions, with global Phase 3 programs in generalized myasthenia gravis and primary Sjögren’s disease.
Recurring news includes clinical-trial starts and data discussions, financial results and balance-sheet updates, private-placement financing, board appointments, investor-conference presentations and Nasdaq inducement grants under the Vor Biopharma Inc. 2023 Inducement Plan. Company announcements also reflect telitacicept regulatory status in China and global development across major autoimmune indications.
Vor Bio (Nasdaq: VOR) has announced a dual fundraising initiative, pricing an underwritten offering and a private placement, aiming for combined gross proceeds of approximately $115.8 million. The underwritten offering includes 15,302,267 shares at $4.30 per share, expected to yield about $65.8 million, set to close around December 9, 2022. Concurrently, 11,627,907 shares will be sold privately to RA Capital for an additional $50 million. Proceeds will target clinical development and general corporate needs.
Vor Bio has announced promising initial clinical data from its Phase 1/2a trial of trem-cel (formerly VOR33) for acute myeloid leukemia (AML). The first patient's results indicate successful engraftment and maintenance of blood counts after treatment with Mylotarg. A total of 7.6 x106 CD34+ cells/kg were infused, achieving 100% donor chimerism and robust hematopoietic reconstitution. No adverse events related to Mylotarg were noted, highlighting the treatment's tolerability. A conference call discussing these developments is scheduled for December 7, 2022.
Vor Bio (Nasdaq: VOR), a clinical-stage company focusing on cell and genome engineering, will participate in several investor conferences. The Piper Sandler 34th Annual Healthcare Conference is scheduled for November 29, 2022, at 9:30 am ET in New York. A fireside chat at the 5th Annual Evercore ISI HealthCONx Virtual Conference will occur on December 1 at 3:05 pm ET, followed by another fireside chat at The JMP Securities Hematology and Oncology Virtual Summit on December 6 at 1:20 pm ET. Webcasts of these events will be available on their website.
Vor Bio reported financial results for Q3 2022, showing a cash position of $136.1 million, projected to fund operations until Q1 2024. R&D expenses increased to $16.9 million, driven by clinical trials and facility expansions. The net loss was $23.8 million. In-house clinical manufacturing is now operational, supporting the IND submission for VCAR33 in H1 2023. The company plans to present initial clinical data for VOR33 by the end of 2022 and has received ATMP status from EMA for VOR33 and VCAR33.
Vor Bio (Nasdaq: VOR) has announced its participation in several upcoming investor conferences. Key events include:
- Credit Suisse 31st Annual Healthcare Conference: Virtual presentation on November 8, 2022.
- Stifel 2022 Healthcare Conference: Fireside chat on November 16, 2022, at 10:20 am EST in New York, NY.
- Jefferies London Healthcare Conference: Fireside chat on November 17, 2022, at 3:15 pm GMT in London, UK.
Webcasts of these events will be available on Vor Bio's investor section.
Vor Bio (Nasdaq: VOR) has appointed Dr. Eyal C. Attar as Chief Medical Officer, bringing over 20 years of clinical experience, particularly in hematologic malignancies. The company anticipates important clinical trial data for VOR33 later this year, alongside an IND submission for VCAR33ALLO planned for early next year. Dr. Attar's expertise in AML and prior roles at Aprea Therapeutics and Agios Pharmaceuticals are expected to enhance Vor Bio's clinical development capabilities. An inducement equity award of 364,000 stock options was granted to Dr. Attar as part of his appointment.
Vor Bio (Nasdaq: VOR) presented promising preclinical data on its novel base editing platform for hematopoietic stem cell (HSC) engineering at the ESGCT Annual Congress in Edinburgh. Their research showcased the successful multiplex deletion of myeloid antigens CD33 and CLL-1, which maintained HSC function and exhibited long-term engraftment without genotoxic risks. This innovative approach is aimed at improving safety and efficacy for treating acute myeloid leukemia (AML), addressing significant challenges in current therapies.
Vor Bio has opened a new in-house clinical manufacturing facility in Cambridge, MA, to enhance the production of engineered hematopoietic stem cells (eHSCs) and CAR-T therapies targeting blood cancers. This facility aims to improve integration across teams, reduce manufacturing time and cost, and boost operational efficiency for ongoing clinical trials. The facility includes four cleanrooms and is designed to comply with Good Manufacturing Practice (cGMP) standards. The company plans to support the IND submission for VCAR33 by mid-2023.
Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, announced its participation in several investor conferences in September 2022.
The events include:
- Morgan Stanley 20th Annual Global Healthcare Conference: September 12, 2022, at 4:50 pm ET in New York, NY
- H.C. Wainwright 24th Annual Global Investment Conference: September 14, 2022, at 8:30 am ET in New York, NY
- Baird’s 2022 Global Healthcare Conference: September 14, 2022, at 10:50 am ET in New York, NY
- Jefferies Cell and Genetic Medicine Summit: September 30, 2022, in New York, NY
A live webcast of the Morgan Stanley chat will be available on vorbio.com.
Vor Bio (Nasdaq: VOR) announced its Q2 2022 financial results, reporting a net loss of $21.7 million, up from $18.4 million in Q2 2021. Cash reserves of $151.1 million will support operations into Q1 2024. The company is on track to share initial clinical data for its lead candidate VOR33 in Q4 2022, which aims to provide a treatment for acute myeloid leukemia (AML). The operational in-house manufacturing facility in Cambridge, MA is also expected to begin operations in Q4 2022, enhancing production capabilities for future therapies.